NCT03802292View on ClinicalTrials.gov

First-In-Man, Healthy Volunteer Study to Evaluate Safety on the Use of YQ23

PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

January 16, 2019

Primary Completion Date

September 20, 2020

Study Completion Date

November 20, 2020

Conditions
Healthy Volunteers
Interventions
BIOLOGICAL

YQ23

Single dose of YQ23 delivered via intravenous route. Ascending dose levels will be evaluated

BIOLOGICAL

Matching Placebo

Single dose of the matching placebo delivered via intravenous route.

Trial Locations (1)

Unknown

Covance CRU Limited, Leeds

All Listed Sponsors
lead

New Beta Innovation Limited

INDUSTRY

NCT03802292 - First-In-Man, Healthy Volunteer Study to Evaluate Safety on the Use of YQ23 | Biotech Hunter | Biotech Hunter